ReproCELL Incorporated

TSE:4978 Voorraadrapport

Marktkapitalisatie: JP¥10.1b

ReproCELL Inkomsten in het verleden

Verleden criteriumcontroles 0/6

ReproCELL has been growing earnings at an average annual rate of 32.3%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 21.1% per year.

Belangrijke informatie

32.3%

Groei van de winst

35.2%

Groei van de winst per aandeel

Biotechs Groei van de industrie31.9%
Inkomstengroei21.1%
Rendement op eigen vermogen-2.1%
Nettomarge-7.2%
Volgende winstupdate13 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Aug 05
ReproCELL Incorporated (TSE:4978) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Jul 17
Here's Why We're Not Too Worried About ReproCELL's (TSE:4978) Cash Burn Situation

Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

Feb 07
Update: ReproCELL (TYO:4978) Stock Gained 33% In The Last Five Years

Opbrengsten en kosten

Hoe ReproCELL geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

TSE:4978 Opbrengsten, kosten en inkomsten (JPY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 242,489-1781,187418
31 Mar 242,426-311,131384
31 Dec 232,506-2181,088429
30 Sep 232,524-3131,057459
30 Jun 232,843-2751,010481
31 Mar 232,953-305984501
31 Dec 222,969-263936468
30 Sep 222,821-306927466
30 Jun 222,518-411893466
31 Mar 222,234-575898535
31 Dec 211,825-505898571
30 Sep 211,661-648875642
30 Jun 211,500-726884713
31 Mar 211,286-812843662
31 Dec 201,257-1,011883626
30 Sep 201,249-945859558
30 Jun 201,111-995859482
31 Mar 201,199-1,016889454
31 Dec 191,173-834886388
30 Sep 191,114-809943317
30 Jun 191,090-750964282
31 Mar 191,088-601971273
31 Dec 181,046-1,950805277
30 Sep 181,018-1,965846264
30 Jun 18969-2,052908233
31 Mar 18926-2,172982191
31 Dec 171,083-1,0191,122203
30 Sep 171,187-7591,071237
30 Jun 171,202-7651,031256
31 Mar 171,257-9111,011276
31 Dec 161,136-1,838882277
30 Sep 161,043-2,150958274
30 Jun 161,069-2,199984282
31 Mar 161,066-1,961979289
31 Dec 151,023-7911,218337
30 Sep 15917-7201,111340
30 Jun 15743-518947316
31 Mar 15567-451736280
31 Dec 14473-359487186
30 Sep 14463-187345147
30 Jun 14462-140268133
31 Mar 14460-133229120

Kwaliteitswinsten: 4978 is currently unprofitable.

Groeiende winstmarge: 4978 is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: 4978 is unprofitable, but has reduced losses over the past 5 years at a rate of 32.3% per year.

Versnelling van de groei: Unable to compare 4978's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: 4978 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).


Rendement op eigen vermogen

Hoge ROE: 4978 has a negative Return on Equity (-2.12%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden